Washington University/ Siteman Cancer Center Lead Academic Site

华盛顿大学/斯特曼癌症中心领导学术网站

基本信息

批准号：
8605719
负责人：
NANCY L BARTLETT
金额：
$ 154.84万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-05-02 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8605719
关键词：
American College of Radiology Imaging Network American College of Surgeons Oncology Group Area Cancer Center Cancer and Leukemia Group B Clinical Trials Clinical Trials Cooperative Group Collaborations Commit Communication Comprehensive Cancer Center Conduct Clinical Trials Correlative Study Development Diagnostic Diagnostic Neoplasm Staging Disorder by Site Eastern Cooperative Oncology Group Enrollment Environment Fostering Goals Gynecologic Oncology Gynecologic Oncology Group Illinois Image Institution Lead Leadership Malignant Neoplasms Malignant neoplasm of lung Medical Oncology Mentors Mentorship Mission Missouri Modality Patients Physicians Play Principal Investigator Prognostic Marker Radiation Oncology Radiation Therapy Oncology Group Radiology Specialty Recording of previous events Research Research Personnel Site Specialist Therapy Clinical Trials Thoracic Oncology Translational Research Universities Washington Work anticancer research biobank cancer therapy design experience improved leukemia/lymphoma malignant breast neoplasm member metropolitan oncology operation professor programs public health relevance tool

项目摘要

DESCRIPTION (provided by applicant): The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) Lead Academic Site is to create a supportive environment that will foster 1) scientific leadership and mentorship, 2) development of cooperative group clinical trials, 3) substantial accrual to clinical trials across the entire NCTN and 4) exceptional conduct of clinical trials. Investigators at WU/SCC are committed to work to enhance the research goals of the NCTN Program and to enroll patients to NCTN trials across the Network. WU/SCC investigators have a long history of enthusiastic participation in the cooperative groups including ACOSOG, ACRIN, CALGB, GOG, and RTOG and will continue to play key roles in the newly merged groups including the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 U10 Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Bryan F. Meyers, MD, MPH (Professor, Thoracic Oncology), Jeff M. Michalski, MD, MBA (Professor, Radiation Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology) and Barry A. Siegel, MD (Professor, Radiology). All members of the senior leadership team have extensive clinical trial experience, including many years of cooperative group involvement, and are committed to providing guidance for an institution-wide cooperative group NCTN UI0. WU/SCC is consistently among the top accruing institutions in each of the cooperative groups with outstanding accrual across many disease sites. Between January 2007 and June 2012, WU/SCC accrued 1633 patients to cooperative group therapeutic trials, an average of 297 patients per year for the last 5.5 years (171 ACOSOG, 1024 CALGB/Alliance, 156 GOG, and 282 RTOG). During this same interval, 727 patients had biospecimens collected and 101 patients were accrued to advanced imaging studies through ACRIN. WU/SCC investigators are highly motivated to contribute to the scientific mission of the NCTN, particularly in the areas of breast cancer, gynecological oncology, thoracic oncology, Gl oncology, GU oncology, leukemia, and lymphoma. Strong translational science in breast cancer, lung cancer, and AML at WU/SCC, along with large institutional biorepositories, will provide many opportunities for unique contributions to correlative studies associated with cooperative group therapeutic trials. This institution-wide UIO will facilitate enhanced communication and collaboration among disease site and modality specialists and improve our potential for contributions to the NCTN operation.

描述（由申请人提供）：拟议的华盛顿大学/斯特曼癌症中心 (WU/SCC) 主要学术站点的基本目标是创造一个支持性环境，以促进 1) 科学领导力和指导，2) 合作团体临床的发展试验，3) 整个 NCTN 临床试验的大量收益 4) 临床试验的特殊实施。 WU/SCC 的研究人员致力于提高 NCTN 计划的研究目标，并通过网络招募患者参加 NCTN 试验。 WU/SCC 的研究者长期以来一直热衷于参与 ACOSOG、ACRIN、CALGB、GOG 和 RTOG 等合作组织，并将继续在新合并的肿瘤学临床试验联盟、ECOG-ACRIN 等新合并的组织中发挥关键作用癌症研究小组和 NRG 肿瘤学。 WU/SCC 将拥有 5 名 U10 首席研究员，组成高级领导团队，包括 Nancy L. Bartlett, MD（医学肿瘤学教授）、Bryan F. Meyers, MD, MPH（胸部肿瘤学教授）、Jeff M. Michalski, MD、 MBA（放射肿瘤学教授），David G. Mutch，医学博士（教授，妇科肿瘤学）和 Barry A. Siegel 医学博士（放射学教授）。高层领导团队的所有成员都拥有丰富的临床试验经验，包括多年的合作组参与经验，并致力于为机构范围的合作组NCTN UI0提供指导。 WU/SCC 在每个合作团体中始终名列前茅的累积机构之列，在许多疾病点的累积表现出色。 2007年1月至2012年6月期间，WU/SCC共招募了1633名患者参加合作团体治疗试验，过去5.5年平均每年297名患者（171名ACOSOG、1024名CALGB/Alliance、156名GOG和282名RTOG）。在同一时间段内，727 名患者收集了生物样本，101 名患者通过 ACRIN 进行了高级成像研究。 WU/SCC 研究人员非常积极地为 NCTN 的科学使命做出贡献，特别是在乳腺癌、妇科肿瘤学、胸部肿瘤学、胃肠道肿瘤学、GU 肿瘤学、白血病和淋巴瘤领域。 WU/SCC 在乳腺癌、肺癌和 AML 方面强大的转化科学以及大型机构生物样本库将为与合作团体治疗试验相关的相关研究提供许多独特贡献的机会。这个机构范围内的 UIO 将促进加强疾病现场和模式专家之间的沟通与合作，并提高我们为 NCTN 运营做出贡献的潜力。